| __timestamp | Apellis Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 302156000 |
| Thursday, January 1, 2015 | 6356782 | 402271000 |
| Friday, January 1, 2016 | 4303743 | 476593000 |
| Sunday, January 1, 2017 | 10463151 | 554336000 |
| Monday, January 1, 2018 | 22639184 | 604353000 |
| Tuesday, January 1, 2019 | 67046483 | 680924000 |
| Wednesday, January 1, 2020 | 139401000 | 737669000 |
| Friday, January 1, 2021 | 176771000 | 759375000 |
| Saturday, January 1, 2022 | 277163000 | 854009000 |
| Sunday, January 1, 2023 | 500815000 | 937300000 |
| Monday, January 1, 2024 | 1009025000 |
Unleashing insights
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Over the past decade, BioMarin Pharmaceutical Inc. and Apellis Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses.
BioMarin, a leader in rare disease therapies, has consistently maintained higher SG&A expenses, peaking at approximately 937 million in 2023, reflecting a steady increase of about 210% since 2014. This growth underscores BioMarin's expansive operational strategies and market penetration efforts.
Conversely, Apellis Pharmaceuticals, known for its innovative treatments in ophthalmology and hematology, has seen a dramatic rise in SG&A expenses, skyrocketing by over 17,000% from 2014 to 2023. This surge highlights Apellis's aggressive market expansion and investment in commercial infrastructure.
These trends offer valuable insights into the strategic priorities and market dynamics of these biopharma giants.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Apellis Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.